Literature DB >> 10654928

Soluble immune mediators in POEMS syndrome with pulmonary hypertension: case report and review of the literature.

L Feinberg1, D Temple, E de Marchena, R Patarca, A Mitrani.   

Abstract

POEMS syndrome is a plasma cell dyscrasia that presents with numerous complications, one of which is rarely pulmonary hypertension. Here we present a case of POEMS syndrome with pulmonary hypertension who improved with steroids and six rounds of plasmapheresis done over 1 month, and we document the baseline immune mediator status and the changes associated with the therapeutic intervention. Serum levels of soluble immune mediators such as interleukin (IL)-5, IL-8, IL-10, and eotaxin were normal at baseline and throughout therapy, whereas those of tumor necrosis factor (TNF)-alpha, soluble TNF-receptor type I (sTNF-RI), IL-6, interferon (IFN)-gamma, IL-2, and sIL-2R, which were abnormally high at baseline normalized with steroids and plasmapheresis. Serum levels of sIL-6R, which were abnormally low at baseline, increased to normal after therapy. The latter results pinpoint not only potential mediators of the systemic manifestations of POEMS syndrome with pulmonary hypertension but also relevant markers in patient follow-up. In this respect, IL-6 has been involved in the pathogenesis of multiple myeloma and Castleman's disease, and the interplay between abnormally high levels of IL-6 and abnormally low levels of its soluble receptor, deficiencies that corrected with therapy in this patient, appears to be particularly relevant to the pathogenic manifestations of POEMS syndrome with pulmonary hypertension. These findings are discussed in the context of our current knowledge of the pathogenesis of pulmonary hypertension and of potential new therapeutic modalities for POEMS syndrome with pulmonary hypertension.

Entities:  

Mesh:

Year:  1999        PMID: 10654928

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  8 in total

1.  An unusual case of pulmonary hypertension in a young male.

Authors:  Carlo Rostagno; Stefania Ciolli; Domenico Prisco
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

2.  Pulmonary morbidity improves after autologous stem cell transplantation in POEMS syndrome.

Authors:  Satish Chandrashekaran; Angela Dispenzieri; Stephen S Cha; Cassie C Kennedy
Journal:  Respir Med       Date:  2014-11-14       Impact factor: 3.415

3.  Bone marrow histopathology in POEMS syndrome: a distinctive combination of plasma cell, lymphoid, and myeloid findings in 87 patients.

Authors:  Linda N Dao; Curtis A Hanson; Angela Dispenzieri; William G Morice; Paul J Kurtin; James D Hoyer
Journal:  Blood       Date:  2011-03-08       Impact factor: 22.113

4.  CD4+ T cells and IFN-γ are required for the development of Pneumocystis-associated pulmonary hypertension.

Authors:  Steve D Swain; Dan W Siemsen; Rebecca R Pullen; Soo Han
Journal:  Am J Pathol       Date:  2013-12-21       Impact factor: 4.307

5.  Pulmonary hypertension in POEMS syndrome.

Authors:  Jian Li; Zhuang Tian; Hao-Yi Zheng; Wei Zhang; Ming-Hui Duan; Yong-Tai Liu; Xin-Xin Cao; Dao-Bin Zhou
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

6.  Pulmonary hypertension complicating multiple myeloma.

Authors:  Udhay Krishnan; Tomer M Mark; Ruben Niesvizky; Irina Sobol
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

7.  POEMS Syndrome Diagnosed 10 Years after Disabling Peripheral Neuropathy.

Authors:  Viet H Nguyen
Journal:  Case Rep Med       Date:  2011-10-15

8.  Severe Pulmonary Hypertension Caused by Smoldering Plasma Cell Myeloma: An Autopsy Case of POEMS Syndrome.

Authors:  Katsuya Chinen; Yasunori Fujioka
Journal:  Case Rep Med       Date:  2012-11-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.